PTPI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PTPI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Petros Pharmaceuticals's EBITDA for the three months ended in Dec. 2024 was $-8.44 Mil. Petros Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was $0.73 Mil. Therefore, Petros Pharmaceuticals's EBITDA margin for the quarter that ended in Dec. 2024 was -1,164.00%.
The historical data trend for Petros Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
EBITDA Margin % | Get a 7-Day Free Trial | -128.70 | -22.28 | -229.07 | -72.35 | -211.54 |
Petros Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
EBITDA Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-351.92 | -92.80 | 14.57 | -82.11 | -1,164.00 |
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's EBITDA Margin % falls into.
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Petros Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as
Petros Pharmaceuticals's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals (NAS:PTPI) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Thank you for viewing the detailed overview of Petros Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Wayne Remell Walker | director | 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103 |
Greg Bradley | director | 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726 |
John D Shulman | director, 10 percent owner | |
Jcp Iii Sm Aiv, L.p. | 10 percent owner | 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
Juggernaut Partners Iii Gp, L.p. | 10 percent owner | 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
Juggernaut Partners Iii Gp, Ltd. | 10 percent owner | 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
Metp Holdings Llc | 10 percent owner | 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
Joshua Silverman | director | IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017 |
Bruce Bernstein | director | 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017 |
Keith Lavan | officer: Chief Financial Officer | 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726 |
Fady Boctor | officer: Pres. & Chief Comm. Officer | 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726 |
Andrew Gesek | officer: President, Timm Medical | 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726 |
Metuchen Therapeutics, Llc | 10 percent owner | 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015 |
Mitchell Arnold | officer: Prin. Acct. Off/Prin. Fin. Off | 200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726 |
From GuruFocus
By GuruFocus News • 02-13-2025
By ACCESSWIRE • 01-17-2024
By ACCESSWIRE • 04-16-2024
By ACCESSWIRE • 09-11-2024
By ACCESSWIRE • 12-19-2024
By ACCESSWIRE • 05-14-2024
By ACCESSWIRE • 05-21-2024
By ACCESSWIRE • 10-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.